Long-Term Outcomes of Rituximab-Treated Adult Patients with Podocytopathies

Overview

Journal J Am Soc Nephrol

Specialty Nephrology

Date 2024 Oct 21

PMID 39431468

Authors

Philipp Gauckler

Anna Matyjek

Seleni Kapsia

Smaragdi Marinaki

Luis F Quintana

Montserrat M Diaz

Catherine King

Sian Griffin

Raja Ramachandran

Balazs Odler

Kathrin Eller

Ayse Serra Artan

Safak Mirioglu

Martin Busch

Maxi Schaepe

Kultigin Turkmen

Chee Kay Cheung

Ruth J Pepper

Gema Fernandez Juarez

Julio Pascual

Pilar Aunon

Clara Garcia-Carro

Antolina Rodriguez

Federico Alberici

Leonella Luzardo

Natalia Chebotareva

Ulf Schonermarck

Loreto Fernandez

Jai Radhakrishnan

Karina Guaman

Yonatan Peleg

Lea Hoisnard

Vincent Audard

Marios Papasotiriou

Nina Krnanska

Vladimir Tesar

Zdenka Hruskova

Annette Bruchfeld

Maria Stangou

Georgios Lioulios

Stanislas Faguer

David Ribes

Sofiane Salhi

Martin Windpessl

Kresimir Galesic

Matija Crnogorac

Nikola Zagorec

Gert Mayer

Andreas Kronbichler

Affiliations

Soon will be listed here.

Citing Articles

Long-term efficacy of Rituximab in steroid dependent and frequent relapsing adult nephrotic syndrome.

Feder O, Amsterdam D, Ershed M, Grupper A, Schwartz D, Kliuk-Ben Bassat O BMC Nephrol. 2025; 26(1):126.

PMID: 40050772 PMC: 11887153. DOI: 10.1186/s12882-025-04035-0.

Nephrotic and Non-Nephrotic Focal Segmental Glomerulosclerosis: Clinical Characteristics, Etiology, and Columbia Classification.

Figueiredo G, Yu L, Jorge L, Woronik V, Dias C Diagnostics (Basel). 2025; 15(2).

PMID: 39857004 PMC: 11763650. DOI: 10.3390/diagnostics15020120.